for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Moderna Inc

MRNA.O

Latest Trade

152.68USD

Change

-6.31(-3.97%)

Volume

5,720,784

Today's Range

151.15

 - 

158.91

52 Week Range

46.13

 - 

189.26

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
158.99
Open
154.11
Volume
5,720,784
3M AVG Volume
210.33
Today's High
158.91
Today's Low
151.15
52 Week High
189.26
52 Week Low
46.13
Shares Out (MIL)
401.53
Market Cap (MIL)
63,838.90
Forward P/E
6.25
Dividend (Yield %)
--

Next Event

Moderna Inc at Bank of America Global Research Healthcare Conference (Virtual)

Latest Developments

更多

Moderna To Deliver 25 Mln Doses Of Its COVID-19 Vaccine To Australia

Moderna Reports Qtrly EPS Of $2.84

Moderna Expands Manufacturing Technology Center In Massachusetts

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Moderna Inc

Moderna, Inc. is engaged in transformative medicines based on messenger ribonucleic acid (mRNA). It has created a platform to improve the underlying pharmaceutical properties of our mRNA medicines. Its platform consists of three areas: mRNA technologies, delivery technologies, and manufacturing processes. It is pursuing mRNA science to minimize the undesirable activation of the immune system by mRNA and to maximize the potency of mRNA once in the target cells. It has advanced in parallel a diverse development pipeline of 21 programs, of which 10 have entered clinical studies and another three have open INDs. Its therapeutics and vaccine development programs span infectious diseases, oncology, cardiovascular diseases, and rare genetic diseases. It has created six modalities prophylactic vaccines, cancer vaccines, intratumoral immmuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics and systemic intracellular therapeutics.

Industry

Biotechnology & Drugs

Contact Info

200 Technology Sq

Cambridge, MA

02139-3578

United States

+1.617.7146500

https://www.modernatx.com/

Executive Leadership

Noubar B. Afeyan

Non-Executive Independent Chairman of the Board, Co-Founder

Stephen Hoge

President

Stephane Bancel

Chief Executive Officer, Director

David W. Meline

Chief Financial Officer

Tracey Franklin

Chief Human Resources Officer

Key Stats

2.56 mean rating - 16 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.1K

2019

0.1K

2020

0.8K

2021(E)

18.3K
EPS (USD)

2018

-4.950

2019

-1.550

2020

-1.960

2021(E)

24.929
Price To Earnings (TTM)
126.77
Price To Sales (TTM)
23.37
Price To Book (MRQ)
16.61
Price To Cash Flow (TTM)
100.22
Total Debt To Equity (MRQ)
4.77
LT Debt To Equity (MRQ)
3.60
Return on Investment (TTM)
19.34
Return on Equity (TTM)
8.10

Latest News

Latest News

UPDATE 1-Australia in 'active talks' with Moderna to produce COVID-19 vaccines onshore

Australia is in "active talks" with COVID-19 vaccine maker Moderna Inc to establish a domestic manufacturing facility for shots, Health Minister Greg Hunt said on Thursday, the day after securing 25 million doses from the company.

Australia in 'active talks' with Moderna to locally produce mRNA vaccines

Australia is in "active talks" with COVID-19 vaccine maker Moderna Inc to establish a domestic manufacturing facility for mRNA vaccines, Health Minister Greg Hunt said on Thursday.

COVID SCIENCE-mRNA vaccines appear effective vs India variant; people with HIV at higher risk for severe COVID-19

The following is a roundup of some of the latest scientific studies on the novel coronavirus and efforts to find treatments and vaccines for COVID-19, the illness caused by the virus.

UPDATE 3-Australia taps Moderna for 25 million COVID-19 shots in vaccination ramp up

Australia on Wednesday tapped Moderna Inc for 25 million COVID-19 vaccine doses, as it tries to speed up vaccination in people under 50 after deciding against AstraZeneca, whose jab has been linked to rare blood clots.

Moderna to deliver 25 million COVID-19 vaccine doses to Australia

Moderna Inc on Wednesday announced a supply pact with Australia for 25 million doses of its COVID-19 vaccine, of which 10 million doses against the original strain of the virus are to be delivered in 2021. (Reporting by Manojna Maddipatla in Bengaluru; Editing by Arun Koyyur...

Japan may approve AstraZeneca, Moderna vaccines as early as May 20 -Nikkei

Japan's government may approve the use of coronavirus vaccines developed by AstraZeneca PLC and Moderna Inc as early as May 20, the Nikkei reported on Friday.

UPDATE 3- Moderna sees no impact on COVID-19 vaccine from potential patent waiver

Moderna Inc on Thursday said it believes countries around the globe would continue buying its COVID-19 vaccine for years even if patents on the shots are waived, noting that rivals would face significant hurdles in scaling up manufacturing.

Moderna says waiving IP rights won't help increase vaccine supply

Moderna Inc said on Thursday that waiving intellectual property rights on COVID-19 vaccines will not help boost supply in 2021 or 2022, a day after U.S. President Joe Biden backed a proposed waiver that is aimed at giving poorer companies access. (Reporting by Manas Mishra...

Moderna raises 2021 sales forecast for COVID-19 vaccine to $19.2 bln

Moderna Inc raised its 2021 sales forecast for its COVID-19 vaccine by 4.3% to $19.2 billion on Thursday, reflecting demand from countries looking to return to normalcy through rapid inoculation.

Moderna booster increases antibodies against COVID-19 variants, early data shows

Moderna Inc said on Wednesday early human trial data shows that a third dose of either its current COVID-19 shot or an experimental new vaccine candidate increases immunity against variants of COVID-19 first found in Brazil and South Africa.

Philippines approves emergency use of Moderna's COVID-19 vaccine

The Philippines' food and drug agency approved on Wednesday the emergency use of U.S. drugmaker Moderna Inc's COVID-19 vaccine in the Southeast Asian nation.

UPDATE 3-Moderna deal, Swedish donation boost COVAX vaccine-sharing platform

* WHO boss heralds "suberb gesture", urges others to follow Sweden

COVAX gets boost from Moderna deal, Sweden's donation of COVID-19 vaccines -GAVI

Moderna will supply 34 million doses of its COVID-19 vaccine this year and Sweden has donated 1 million AstraZeneca shots to the global COVAX programme, a small boost as it struggles to get stocks to inoculate the world's poorest people.

UPDATE 3-Help wanted: Lonza seeks workers to lift Moderna vaccine output

* Three lines for Moderna vaccine expected to hit capacity by June

Lonza says 3 Moderna vaccine ingredient lines to be at capacity by end-June

Three new Lonza production lines that manufacture ingredients for Moderna's COVID-19 vaccine are due to be producing at capacity by the end of June, Chief Executive Pierre-Alain Ruffieux said on Thursday in an interview.

Spain's Rovi will double its capacity to bottle Moderna's COVID-19 vaccines

Spanish contract drugmaker Rovi said on Thursday it will double its capacity to bottle COVID-19 vaccines for Moderna.

BRIEF-Moderna Announces Additional Investments To Increase Global Supply For COVID-19 Vaccine To Up To 3 Bln Doses In 2022

* MODERNA INC - ANNOUNCES ADDITIONAL INVESTMENTS TO INCREASE GLOBAL SUPPLY FOR COVID-19 VACCINE TO UP TO 3 BILLION DOSES IN 2022

Switzerland's Lonza to boost production for Moderna COVID-19 vaccine

Contract drug manufacturer Lonza plans to double Swiss production capacity for Moderna's COVID-19 vaccine, helping the U.S. drugmaker boost total output to as many as 3 billion doses in 2022. (Reporting by John Miller Editing by Riham Alkousaa)

UPDATE 1-U.S. govt boosts Moderna COVID-19 vaccine contract to $1.25 bln

Moderna Inc said on Wednesday the U.S. government had agreed to increase the contract for the company's COVID-19 vaccine by $236 million to roughly $1.25 billion, to include additional costs related to the shot's studies.

UPDATE 1-Nestle staff sought to help Lonza production for Moderna vaccine -Swiss TV

Drugmaker Lonza Group, under pressure to find workers to help speed production of Moderna Inc's COVID-19 vaccine, is recruiting temporary employees from food giant Nestle to staff Swiss plants making ingredients for the shot, state broadcaster RTS said on Tuesday, citing...

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up